Eli Lilly
has parlayed its GLP-1 dual-agonist tirzepatide (Mounjaro/Zepbound) into a broader portfolio strategy spanning diabetes, obesity and expanded cardiometabolic indications, reinforcing its position at the January 2026 JPMorgan Healthcare Conference even amid looming patent challenges.
- Country
- United States
- Ticker
- LLY
small-molecule
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Drug & vaccine development | therapeutics-platforms | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.